Exchange Traded Concepts LLC Purchases 46,773 Shares of Becton, Dickinson and Company $BDX

Exchange Traded Concepts LLC raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 56.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 129,286 shares of the medical instruments supplier’s stock after acquiring an additional 46,773 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Becton, Dickinson and Company were worth $25,091,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Becton, Dickinson and Company by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock valued at $6,074,750,000 after purchasing an additional 147,041 shares during the period. State Street Corp grew its stake in Becton, Dickinson and Company by 3.4% during the third quarter. State Street Corp now owns 13,872,395 shares of the medical instruments supplier’s stock worth $2,596,496,000 after purchasing an additional 459,219 shares during the period. First Eagle Investment Management LLC grew its stake in Becton, Dickinson and Company by 13.8% during the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier’s stock worth $1,870,653,000 after purchasing an additional 1,208,218 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Becton, Dickinson and Company by 7.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier’s stock worth $1,712,715,000 after purchasing an additional 636,138 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in Becton, Dickinson and Company by 9,056.3% in the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock valued at $979,290,000 after buying an additional 5,174,944 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 1.8%

NYSE BDX opened at $154.52 on Friday. The company has a market cap of $44.00 billion, a price-to-earnings ratio of 25.21, a P/E/G ratio of 11.41 and a beta of 0.24. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35. The business has a 50 day moving average price of $180.63 and a 200-day moving average price of $187.63. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same period last year, the business earned $3.43 EPS. Becton, Dickinson and Company’s quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has approved a share buyback plan on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on BDX shares. Royal Bank Of Canada set a $172.00 price target on Becton, Dickinson and Company in a report on Tuesday, February 10th. Argus dropped their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research report on Monday, March 23rd. TD Cowen increased their target price on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Zacks Research cut shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 11th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research note on Tuesday, February 10th. Six research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $191.62.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director owned 36,763 shares in the company, valued at $6,713,291.43. This represents a 2.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 2,713 shares of company stock valued at $536,881 over the last quarter. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.